PT - JOURNAL ARTICLE AU - Jean-Claude Nguyen Van AU - Camille Gerlier AU - Benoît Pilmis AU - Assaf Mizrahi AU - Gauthier Péan de Ponfilly AU - Amir Khaterchi AU - Vincent Enouf AU - Olivier Ganansia AU - Alban Le Monnier TI - Prospective evaluation of ID NOW COVID-19 assay used as point-of-care test in an Emergency Department AID - 10.1101/2021.03.29.21253909 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.29.21253909 4099 - http://medrxiv.org/content/early/2021/04/04/2021.03.29.21253909.short 4100 - http://medrxiv.org/content/early/2021/04/04/2021.03.29.21253909.full AB - Background Rapid testing for COVID-19 has been clearly identified as an essential component of the strategy to control the SARS-CoV-2 epidemic, worldwide. The ID NOW COVID-19 assay is a simple, user-friendly, rapid molecular biology test based on nicking and extension amplification reaction (NEAR).Objectives The aim of this study was to evaluate the ID NOW COVID-19 assay when used as a point-of-care test (POCT) in our Emergency Department (ED).Type of study This prospective study enrolled 395 consecutive patients; paired nasopharyngeal swabs were collected from each study participant. The first swab was tested with the ID NOW COVID-19 assay at the point-of-care by ED nurses. The second swab was diluted in viral transport medium (VTM) and sent to the clinical microbiology department for analysis by both the RT-PCR Simplexa test COVID-19 Direct assay as the study reference method, and the ID NOW COVID-19 assay performed in the laboratory.Results Nasopharyngeal swabs directly tested with the ID NOW COVID-19 assay yielded a sensitivity, specificity, PPV and NPV of 98.0%, 97.5%, 96.2% and 98.7%, respectively, in comparison with the RT-PCR study reference assay. When the ID NOW COVID-19 assay was performed in the laboratory using the VTM samples, the sensitivity decreased to 62.5% and the NPV to 79.7%. Three false negative test results were reported with the ID NOW COVID-19 assay when performed using undiluted swabs directly in the ED; these results were obtained from patients with elevated CT values (>30).Conclusion We demonstrated that the ID NOW COVID-19 assay, performed as a point of care test in the ED using dry swabs, provides a rapid and reliable alternative to laboratory-based RT-PCR methodsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study followed the Standards for Reporting Diagnostic Accuracy study (STARD) guidelines and was favourable approved by the local clinical ethic committee board called Comite de protection des Personnes Nord Ouest Number IRB 2020-A02758-31. Informed oral consent for participation was obtained from each participant, in accordance with French law.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNone